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 Urinary carcinoma is one of the most prevalent cancers across the United States 
and is among the leading cause of cancer related morbidities. With muscle-invasive 
urinary carcinoma having only 15% survival at stage T4, diagnostic tools of this type of 
cancer is necessary. This work sought to characterize a model of urothelial carcinoma 
into a specific muscle-invasive bladder cancer subtype, which has important implications 
in for prognosis, development of targeted therapeutic agents, and disease management. 
Our laboratory has developed an immortalized uroepithelial cell line, UROtsa, which can 
be malignantly transformed by arsenite (As+3) and Cd2+ and has been shown to produce 
colonies on soft agar and tumors in nude mice. We therefore sought to determine if which 
subtype of muscle-invasive bladder cancer in our six As3+ and seven Cd2+-transformed 
cell lines and heterotransplant tumors. Real-time reverse transcriptase polymerase chain 
reaction (RT-PCR) was used to determine mRNA levels of 25 marker genes of basal and 
luminal subtypes of muscle-invasive bladder cancer. Western blotting and 
immunohistocemical analysis of select markers was used to evaluate protein expression. 
Data indicated that the expression of the 25 marker genes in the As3+ and Cd2+-
transformed tumors was increased in the basal subtype compared to the luminal subtype. 
This same expression pattern was also seen in the transformed As3+ and Cd2+ cell lines 
and spheroids, or putative cancer stem cells, derived from our transformed cell lines via 
culture in serum-free media in low attachment flasks. Next, we sought to determine the 
mRNA and protein expression in our non-tumorigenic parental UROtsa cell line. We 
determined the parental UROtsa cell line had increased expression of the basal marker 
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genes and this was further increased in the spheroids, while expression of the luminal 
marker genes was seen to be further decreased in expression in the spheroids.  
 Due to the observations seen in the mRNA expression of the spheroids, we 
became interested in the ability of these cells to maintain their gene signature when 
replaced back into the cell culture conditions of the original cell line. To do this, one As3+ 
cell line was grown in serum media and cell culture flasks that promote attachment. From 
there, the cells were placed into low attachments flasks with serum-free media to produce 
spheroids. Once grown, the cells were reintroduced into cell culture flasks that promote 
cell attachment with serum-containing media and harvested once reaching confluency 
(P1) and passages 4 and 8 (P4 and P8). Microarray analysis of these samples found that 
there were 4,415 differentially expressed genes when comparing the original cell line to 
the spheroid. This number decreased at each comparison of the passages to the cell line 
with 1,290, 452, and 191 differentially expressed genes compared to the cell line at P1, 
P4, and P8 respectively. This data indicated that the replacement of our spheroids into 
cell culture conditions identical to the original cell line promoted the reversal of the 
spheroids into our original cell line cultures. We next sought to understand if the gene 
signature of the spheroids would be maintained if they were cultured in conditions of 
flasks that promote cell attachment with serum-free media in the same As3+ transformed 
cell line, but also a Cd2+ cell line and our original parental UROtsa cell line. By 
performing real-time RT-PCR analysis of the 25 muscle-invasive bladder cancer marker 
genes, we found the number of differentially expressed genes compared to the cell line 
and either the spheroid or subsequent passages was relatively stable with at least 68% of 
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the genes being differentially expressed by P8. This data demonstrates we have a unique 






 Urinary carcinoma accounts for a significant number of cancer morbidity and 
mortality with an estimated 430,000 new cases diagnosed in 2012 (Antoni, et al., 2016) 
and 115,000 deaths each year (Meliker & Nriagu, 2007). Incidence rates are 3 to 4 times 
higher in men than in women and the disease prevalence increases with age; 80% of cases 
in occur in patients ages 50 to 79 (Wai & Miller, 2002). Despite this type of cancer being 
only the fourth most common in males and ninth most common in females (Crawford, 
2008), it is the most expensive cancer from diagnosis to death with the annual cost in 2013 
being $US4.25 billion (Yeung, Dinh, & Lee, 2014).  
 Urinary carcinoma typically arises from the transitional cells of the bladder, termed 
the urothelium, and accounts for 95% of all diagnosed cases (Malats & Real, 2015). These 
tumors can be of two types: a low-grade, non-invasive tumor, which occurs 70% of the 
time with high rates of recurrence, but infrequently progresses to muscle invasion or an 
aggressive, muscle-invasive disease with 5-year survival rates of less than 50% (Yousef & 
Gabril, 2017).  
Anatomy of the Urinary Bladder 
 The urinary bladder is a muscular organ that functions to collect and store urine 
before it is excreted from the body. As mentioned above, the bladder consists of specialized 
epithelial cells called the urothelium, which has properties to allow for filling and voiding 
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in at least two ways. First, the bladder, much like the stomach, is highly wrinkled, which 
allows for the storage of urine by unfolding of the walls of the bladder. Secondly, during 
filling, the urothelium becomes thinner due to a change in the morphology of the cells that 
it is comprised of (Apodaca, 2004). Three types of cells coat the surface of the urothelium: 
umbrella, intermediate, and basal cells. The outermost cells are the umbrella cells that are 
unique to the urothelium and which form a barrier that functions to prevent the entry of 
pathogens and controls the intake of molecules into the underlying tissues layers. Sitting 
just below the umbrella cells are the intermediate cells that may be one to several layers 
thick and are rapidly regenerated. The bottom-most layer of the urothelium is comprised 
of the basal cells, which form a single layer that is in contact with the connective tissue 
below. These cells have a low mitotic index and contain the urothelial stem cells, which 
play a critical role in regeneration.  
 The sub-urothelium or lamina propria is comprised of an extracellular matrix, 
which contains fibroblasts, adipocytes, nerve endings, blood vessels, and the muscularis 
mucosae muscle layer. Deep to this layer is the detrusor layer that contains three layers of 
smooth muscle bundles of the detrusor muscle (inner longitudinal, middle circular, and 
outer longitudinal) along with connective tissue and interstitial cells. This muscle of the 
bladder is covered by a thin membranous connective tissue termed the external serosa and 
is surrounded by perivesical fat in the abdominal cavity.  
Signs and Symptoms of Urinary Carcinoma 
 The most common symptom of urinary carcinoma is gross painless hematuria, also 
known as the presence of blood in the urine. This symptom presents itself in 85% of 
patients at initial diagnosis (Alishahi, Dyrne, Goodman, M., & Baxby, 2002). The second 
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most common symptom is asymptomatic microscopic hematuria with up to 10% of patients 
diagnosed with urinary carcinoma (Metts, Metts, Milito, & Thomas Jr., 2000). A study of 
1,046 patients, 657 and 389 presenting with microscopic and gross hematuria respectively, 
found that 25% of those presenting with gross hematuria had a urological malignancy 
compared to only 3.7% of patients with microscopic hematuria (Alishahi, Dyrne, 
Goodman, M., & Baxby, 2002). In addition, of the 1,930 patients enrolled in a study at a 
hematuria clinic, 12% were found to have urinary carcinoma (Khadra, Pickard, Charlton, 
Powell, & Neal, 2000). The remaining patients that do not present with the symptoms 
mentioned above do present with signs that mimic other common urological diseases, such 
as urinary tract infections.  
Muscle-Invasive Urinary Carcinoma 
 At the time of diagnosis, approximately one-third of urinary tumors present as non-
papillary lesions and have a high propensity for metastasis (Malkowicz, et al., 2007). These 
tumors consist of those staged from T2 to T4. These high-grade tumors have overall 5-year 
survival rates of 68% for patients with a T2 diagnosis to only 15% for those with T4 
(Goebell & Knowles, 2010). The invasion of a tumor into the muscularis propria is staged 
as T2, while stages T3 and T4 are characterized by the invasion of the perivesical soft tissue 
or invasion into an adjacent organ, which include the vagina, uterus, prostate, pelvic wall 
or abdominal wall, respectively (Cheng, Montironi, Davidson, & Lopez-Beltran, 2009). 
With evidence supporting differences in morphology and survival rates, it is hypothesized 




 Animal studies have proposed the expression of the SV40 large T antigen to 
inactivate the tumor protein p53 (TP53) and retinoblastoma (RB) pathways to induce non-
papillary, invasive urinary carcinoma (Zhang, Pak, Shapiro, Sun, & Wu, 1999). The p53 
family of transcription factors functions to regulate vital cell processes, which include 
differentiation, proliferation, and control over cell death and survival (Kaghad, et al., 
1997). The RB1 protein is a negative regulator of the cell cycle by controlling progression 
through the G1 phase (Goodrich, Wang, Yue-Wei, Lee, & Lee, 1991). Inactivation of both 
TP53 and RB proteins leads to loss of cell cycle control, which in turn affects many aspects 
of tumorigenesis, such as differentiation, survival, senescence, and genomic stability.   
 
Figure 1. Urinary carcinoma staging according to the TMN system (Adapted from 
van der Meijden A. P., 1998). 
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  Another frequently found mutation in invasive bladder tumors is 
phosphatidylinositol (3,4,5)-trisphosphate [PtdIns(3,4,5)P3] phosphatase and tensin 
homolog (PTEN). PTEN is involved in the conversion of lipid second messengers, which 
antagonizes signaling cascades downstream of receptor tyrosine kinases (RTKs) and 
phosphatidylinositol-3-kinase (PI3K) (Maehama & Dixon, 1998). The inactivation of 
PTEN leads to the dysregulation of the mammalian target of rapamycin pathway (mTOR), 
which in turn inhibits its blocking of bladder tumors (Puzio-Kuter, et al., 2009).  
Diagnosis of Muscle Invasive Urinary Carcinoma 
 Muscle-invasive tumors are diagnosed after further investigation into the cause of 
hematuria. While urine cytology studies have poor sensitivity in detecting low-grade 
cancers (Badalament, Fair, Whitemore Jr., & Melamed, 1988), they are highly predictive 
of high-grade cancers (Droller M. J., 1998). Recently, there have been proposed markers 
in voided urine that may help in the detection of bladder cancer. A promising assay, the 
bladder tumor antigen (BTA) test, detects the release of extracellular matrix proteins from 
urinary carcinoma (Sarodsy, et al., 1997). However, specificity of high-grade carcinomas 
may be affected by infections of the urinary tract, the presence of stones, and other causes 
of inflammation, which deems this assay unreliable for cancer detection (Droller M. J., 
1998). A second molecule being tested for its potential as a diagnostic tool for urinary 
carcinoma is telomerase, a ribonucleoprotien enzyme that functions to produce telomeres 
(Lin, et al., 1996). Detection of telomerase levels in voided urine have been found to have 
a sensitivity of 87.5% for high-grade tumors and an overall specificity of 70% for both 




Treatment of Muscle Invasive Urinary Carcinoma 
 Along the same ideals as low-grade tumors, the standard treatment for muscle 
invasive urinary carcinoma is radical cystectomy with lymph node dissection (Sridhar, 
2017). This procedure is not without drawbacks; in up to as much as 64% of patients, 
radical cystectomy leads to peri- and postoperative complications within the first three 
months post-surgery (Donat, et al., 2009) and failure occurs in 70% to 80% of patients with 
aggressive disease (Skinner & Lieskovsky, 1984). 
 With the global life expectancy increasing yearly, there will be a larger population 
of patients with bladder cancer who have an advanced disease and radical cystectomy will 
no longer be a viable option for treatment. A study found that 25% of patients ages 70-79 
and 40% of patient’s ages 80-89 were treated with observation alone (Gray, et al., 2013). 
In addition, younger patients who wish to avoid the complications associated with radical 
cystectomy may be candidates for other types of treatments, which include partial 
cystectomy, transurethral resection of the bladder tumor (TURBT), chemotherapy and 
radiation therapy.  
 In order to give patients a better chance of survival and remission, neoadjuvant and 
perioperative chemotherapies have been developed. For neoadjuvant chemotherapy, 
cisplatin-based is recommended by both the North American and European guidelines 
(Clark, et al., 2016) (Witjes, et al., 2016). Different combinations of drugs have been tested 
and common regimens include methotrexate, vinblastine, doxorubicin, and 
cyclophosphamide (MVAC) and gemcitabine plus cisplatin (GC) (Galsky, et al., 2015). 
For those who are unfit for cisplatin-based therapy and those who fail to respond to such 
treatment, other options have been explored, such as carboplatin-based drug combinations 
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that have resulted in overall survival rates of 9 months (De Santis, et al., 2012). By instilling 
this multidisciplinary approach to treating urinary carcinoma, hopefully more patients will 
have an easier time managing their disease, a better quality of life, and have more positive 
outcomes.  
 The need for more therapy options for bladder tumors and the investigation of 
immunotherapies for other types of cancers has led to the development of drugs as new 
treatment tools. One therapeutic avenue that has emerged as a promising target is the 
programmed cell death protein 1 (PD-1) and programmed death ligand 1/2 (PD-L1/2) 
pathway. Under homeostatic conditions, PD-1 functions to regulate T cell responses by 
interacting with PD-L/1/2. However, in urinary carcinoma, PD-1 and PD-L1 are 
upregulated, which through their interaction promotes T-cell exhaustion (Tumeh, et al., 
2014). By blocking the interaction with the PD-1 receptor with antibodies, there is a 
restoration of T-cell function (Chism, 2017).    
Molecular Subtypes of Muscle-Invasive Urinary Carcinoma 
 Understanding the molecular expression patterns of heterogeneous tumors could 
lead to improved therapeutic strategies by finding new molecules to target and give insight 
into how individual tumors will respond to therapies. This was first accomplished by 
analyzing gene expression patterns in normal and malignant breast cancer tissue along with 
cell lines and clustering all the samples according to their patterns of expression. The study 
found four groups of samples that had different molecular features and were named 
ER+/luminal-like, basal-like, Erb-B(II) and normal (Perou, et al., 2000). This same idea 




 An investigative group from the University of North Carolina at Chapel Hill sought 
to understand the intrinsic molecular subtypes of high-grade bladder carcinoma. By 
analyzing 262 high-grade muscle-invasive tumors from public datasets and 49 high-grade 
tumors, they found two groups, named K1 and K2, which had different gene expression 
signatures. Clustering of the K1 data set found high levels of the high molecular weight 
keratins, specifically keratin 14 (KRT14), keratin 5 (KRT5), and keratin 6B (KRT6B), 
along with the cluster of differentiation molecule 44 (CD44). Conversely, the K2 cluster 
expressed high levels of uroplakins, specifically uroplakin 1B (UPK1B), uroplakin 2 
(UPK2), and uroplakin 3 (UPK3), and the low molecular weight keratin, keratin 20 
(KRT20). Furthermore, they performed ingenuity pathway analysis (IPA) and found the 
tumors in the K1 cluster were associated with carcinogenesis and cell survival and 
movement (Damrauer, et al., 2014).  
 A second group from Lund University in Sweden analyzed 144 urinary carcinomas 
by whole genome array-comparative genomic hybridization and mutational analysis of 
genes known to be implicated in the development of urinary tumors. Their clustering 
results found two intrinsic molecular subtypes, which they proceeded to name MS1 and 
MS2. Further analysis of the two groups found distinct enrichment of genes between the 
subtypes with cell cycle genes, cellular transformation, and genomic instability in the MS2 
subtype. Taken together, these particular gene enrichments suggest the MS2 subtype to be 
more aggressive than MS1. The mutational analysis found distinct patterns for mutations 
in the genes implicated in the two hypothesized pathways of the development of urinary 
carcinoma. Activating mutations in fibroblast growth factor receptor 3 (FGFR3)/ 
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) were 
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found in the MS1 tumors, while alterations in TP53/ MDM2 proto-oncogene (MDM2) and 
a loss of RB1 were significant in MS2 tumors (Lindgren, et al., 2010).  
 A follow-up study by this group extended their previous research and found 5 major 
subtypes of urinary carcinoma: urobasal A, urobasal B, genomically unstable, squamous-
cell carcinoma (SCC) like, and a heterogeneous, infiltrated group. The urobasal A tumors 
had elevated expression levels of FGFR3, cyclin D1 (CCND1), and tumor protein 63 
(TP63) and showed a good prognosis. The genomically unstable tumors were characterized 
by TP53 mutations and genes found to be associated with tumor progression and 
recurrence, such as karyopherin subunit alpha 2 (KPNA2) and heme oxygenase 1 
(HMOX1) (Staack, et al., 2002). High expression of the basal keratins KRT4, KRT6A, 
KRT6B, KRT6C, KRT14, and KRT16 were found in the SCC-like tumors. The urobasal 
B tumors were enriched in FGFR3 mutations along with FGFR3, CCND1, and TP63 gene 
expression, similar to the urobasal A subtype. However, this group showed expression of 
some keratins of the SCC-like group and TP63 mutations, which led researchers to believe 
this group is more progressed than the urobasal A group. Finally, the infiltrated tumor 
group was characterized by the presence of immunologic and myofibroblast cells (Sjödahl, 
et al., 2012). 
 The final investigative team to pioneer this research in urinary carcinoma out of the 
University of Texas MD Anderson Cancer Center performed whole genome mRNA 
expression profile on 73 TURBT muscle-invasive samples. By doing this they identified 
three distinct subtypes: basal, luminal, and p53-like. The basal tumors were characterized 
by upregulated gene expression of CD44, KRT5, KRT6, KRT16, and CDH3 and was 
associated with shorter overall survival and disease-specific survival. On the other hand, 
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luminal tumors were enriched in high expression and mutations of FGFR3. The 
transcription factors peroxisome proliferator activator receptor gamma (PPARγ) and its 
coactivator fatty acid binding protein 4 (FABP4) were also found to be strongly expressed 
in luminal tumors (Choi, et al., 2014).  
 Taken altogether, more aggressive tumors in the above studies, namely basal, were 
characterized by areas of squamous differentiation and high expression of high molecular 
weight keratins (KRT5, KRT6, KRT14, and KRT16) along with CDH3 and CD44. These 
tumors were found to have mutations in RB1 and were associated with shorter overall 
disease-specific survival and carcinogenesis. In contrast, tumors that were found to be less 
aggressive, or luminal, were characterized by mutations in FGFR3 and high expression 
levels of uroplakins and KRT20 along with the transcription factors PPARγ and FABP4.  
Tumor-Derived Spheroids as an In Vitro Model System 
 Two-dimensional (2D) monolayer cell cultures are an indispensable tool that 
allows researchers to understand many functions and characteristics of tissue samples, as 
well as an excellent model to test new therapeutics without using animals. However, 
recent discoveries have found that three-dimensional (3D) cell culture models offer 
benefits that 2D cultures cannot. For example, in 2D cultures, cancer cells rely on 
adherence to a flat surface and thus all cells are exposed to a similar amount of nutrients 
and growth factors, but 3D cultures can more closely mimic the in vivo environment 
where cells in the center of a tumor would be hypoxic and have reduced proliferation.  
 One type of 3D cell culture model system utilizes the growth of cancer cell lines 
in low-attachment cell culture flasks and serum-free media, which produces spherical, 
free-floating cells, which are named tumorspheres or spheroids. This type of cell 
26 
 
culturing allows for the growth and expansion of a subpopulation of cells from the overall 
cell line, in which the cells show characteristics of cancer stem cells. The first description 
of cancer stem cells in free-floating culture came from the dissociation of brain tumors 
(Singh, et al., 2003) and in the subsequent years, a wide range of solid tumors and cancer 
cell lines have given rise to spheroids. This type of stem cell shares characteristics with 
typical stem cells such as self-renewal and pluripotent capacity (Reya, Morrison, Clarke, 
& Weissman, 2001). Although they have these features, cancer stem cells are a distinct 
population of cells that are essential for the development of a tumor and their relationship 
to the overall population of cells in culture is unknown.   
Risk Factors of Urinary Carcinoma 
 The lifestyle choices that we make have a large impact on our health. Some of these 
decisions leave us more susceptible to developing specific types of cancer. For urinary 
carcinoma, many risk factors increase a person’s chances of developing this type of cancer. 
To illustrate this, research has found that men who smoke have a two-fold increase in 
developing bladder tumors, while women who smoke have a four-fold increase compared 
to those who never smoke (Reedman, Silverman, Hollenbeck, Schatzkin, & Abnet, 2011). 
On the contrary, there was found to be no association of alcohol and no strong association 
of coffee with urinary carcinoma (Pelucchi & La Vecchia, 2009).  
 Environmental risk factors also play a role in the development of urinary tumors. 
For those who reside in Egypt and other countries in the eastern hemisphere, schistosoma 
haematobium (S. haematobium), whose life cycle is in freshwater snails and humans, has 
been found to cause 27% of urinary carcinoma cases in Cairo, Egypt (Elsebai, 1977). The 
most notable environmental risk factor of urinary carcinoma is occupational exposures. 
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Over a century ago, it was first noted that dye workers in Germany were found to have 
incidence of bladder tumors (Johansson & Cohen, 1998). It was found that the causative 
agent was 2-Naphthylamine, a now recognized carcinogenic agent of bladder cancer 
(Humans, 2010). Since then, it has been estimated that urinary carcinoma from 
occupational exposures has resulted in up to 27% of the total number of cancers (Delclos 
& Lerner, 2008).  
Heavy Metals 
 Of particular interest to our laboratory are the heavy metals arsenic and cadmium 
(Cd2+), two of the four heavy metals that are known to be carcinogenic to humans (Ernst 
& Theriault, 1984). Since both of these heavy metals have been associated with an 
increased risk of many cancers, they have been designated by the International Agency for 
Research as a Group 1 human carcinogen (Cancer, Cadmium and Cadmium Compounds, 
1993) (Cancer, Arsenic and Arsenic Compounds, 2002).  
Exposure and Metabolism of Arsenic 
 Of the three biological groups of arsenic compounds, inorganic arsenic (iAs) is 
associated with acute and chronic effects through two common ways of exposure: 
inhalation from industrial sources or ingestion of contaminated drinking water. In addition, 
arsenic is present in soil with concentrations up to 40µg/g (Cancer, Monographs on the 
Evaluation of the Carcinogenic Risk of Chemicals to Man: Some Metals and Metallic 
Compounds, 1980), which contaminates crops. This has negative implications on rice, 
which is ten times more effective at absorbing arsenic compared to other grains (Schmidt, 
2015). Given the strong evidence of adverse health effects that can be attributed to iAs 
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exposure, understanding the metabolism of this metalloid is a necessary part to elucidating 
its role in carcinogenesis.  
 iAs comes in two forms: arsenite (As3+) and arsenate (As5+), of which As3+ is the 
more common of the two. Once in the body, iAs can be metabolized by participation in 
oxidation-reduction reactions and methylation. This happens when As5+ is reduced to As3+ 
and this product can undergo oxidative methylation. The methylation of As3+ plays an 
important role in the metabolism of iAs as it is converted into mono-methylated (MMA) 
and di-methylated (DMA), which are secreted in urine. DMAs are the predominant 
metabolite secreted in the urine, accounting for 60-80% of iAs (Drobna, Styblo, & Thomas, 
2009). Subsequent studies on methylated arsenals found these metabolites were strong 
cytotoxins and inhibitors of enzymes, even more so than As3+ (Thomas, Styblo, & Lin, 
2001). Taken together, it should be known that the metabolism of iAs produces more 
reactive species that could play a role in the toxicity and carcinogenic of arsenic. An 
alternative model of the methylation of arsenic has been proposed. Instead of undergoing 
oxidative methylation, arsenic is bound to cellular thiols and this is the substrate for its 
methylation. The formation of the arsenic-thiol complexes, which could be cellular thiols 
or in glutathione (GSH), which undergo hydrolysis rather than oxidative methylation 
(Hayakawa, Toru, Kobayashi, Cui, & Hirano, 2005).   
The Role of Arsenic and Carcinogenesis 
 The mechanisms of which arsenic causes the development of cancer in humans has 
not been fully elucidated. As previously illustrated, the metabolism of arsenic may induce 
the production of toxic free radicals, which can cause damage to lipids, proteins, and 
deoxyribonucleic acid (DNA). In addition, As3+ exposure to multiple mammalian cell lines 
induced the expression of mitogen-activated protein kinase (MAPK) pathways, 
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intermediate early genes (IEGs), and the activation of the transcription factor activator 
protein 1 (AP-1) (Beyersmann, 2002). The expression of these pathways and genes 
supports the hypothesis that cell proliferation occurs in response to arsenic, which may lead 
to neoplastic growth. Furthermore, other studies found that As3+ inhibited the activation of 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) by the inhibition of 
I-κB kinase, which is required for phosphorylation and subsequent degradation of the I-κB 
inhibitor (Kapahi, et al., 2000). This in turn leads to a down regulation of NF-κB induced 
genes and stimulation of cell proliferation.  
Arsenic and its Implications in Urinary Carcinoma 
 There is mounting evidence showing arsenic is carcinogenic to humans, 
specifically causing cancers of the bladder, lung, kidney, and skin. With millions of people 
around the globe consuming drinking water contaminated with arsenic, this is a significant 
cause of urinary carcinoma. The current United States drinking water standard for arsenic 
is at or below a concentration of 10 parts per billion, but it is estimated that over 300,000 
people drink water with arsenic levels above the set standard level (Corporation, 1987).  
 The most extensive epidemiological studies on the effects of iAs and urinary 
carcinoma were conducted on a population of individuals that inhabited the southwest coast 
of Taiwan. With deep artesian wells contaminated with arsenic, endemic rates of blackfoot 
disease, pigmented, and hyperkeratotic skin lesions were detected. This prompted 
researchers to study rates of cancer in the area and found the mortality risk ratios for bladder 
cancer was 28.7 for men and 65.4 for women at the highest level of arsenic exposure, where 
a risk ratio of greater than one is interpreted as the outcome is increased by the exposure 
(Smith, et al., 1992). Despite this promising looking evidence, it has been suggested that 
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the arsenic in the water was not the sole cause of cancer and averages from large groups 
instead of individual exposure data was used to draw conclusions, which may render this 
study showing false results.  
 More recent studies have considered the criticisms of the study in Taiwan and 
provided evidence that ingested arsenic does indeed lead to the development of urinary 
carcinoma. Two large studies took place in South America, the first being in a province of 
Argentina called Cordoba. The study found the average level of arsenic in their drinking 
water to be 178µg/L, which caused their mortality rates of urinary carcinoma to be double 
the national average (Hopenhayn-Rich, et al., 1996). The second study which took place in 
Northern Chile found mortality of urinary carcinoma was six to eight fold higher in a 
population exposed to river water with arsenic levels of approximately 600µg/L (Smith, 
Goycolea, Haque, & Biggs, 1998).  
 Contrary to the aforementioned studies, a population-based case-control study in 
southeastern Michigan exposure individuals to between 10 and 100µg/L of arsenic found 
no increase in urinary carcinoma risk. This study included 411 cases of cancer and found 
when comparing those who were exposed to >10µg/L to those who were exposed to 
<1µg/L, there was no evidence an association between arsenic exposure at low-level 




Figure 2. Proposed mechanisms of arsenic toxicity and carcinogenesis (Adapted from Kitchin & Wallace, 2007 and Li & Chen, 
2016).
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Exposure and Metabolism of Cadmium 
 Humans are exposed to Cd2+ via a few sources such as inhalation of industrial 
pollution, contamination of top soil, which is absorbed into growing plants, and cigarette 
smoking. The average human intakes between 1-3µg/day of cadmium and this amount is 
doubled in smokers who consume a pack a day (Registry, 2012). The half-life of Cd2+ in 
humans is estimated to be more than 20 years (Satarug, et al., 2005), which allo  ws it to 
be efficiently trapped in the body and cause toxicity.  
 Once Cd2+ is in the body, it is transported via receptors in different types of cells 
where it undergoes metabolism by binding to members of the metallothionein (MT) family. 
MTs are proteins that are rich in cysteine and the major zinc-binding protein (Klaassen, 
Liu, & Choudhuri, 1999). By binding to MTs, Cd2+ is unable to participate in other 
reactions and is subject to detoxification. A second intracellular Cd2+ scavenger is 
glutathione (GSH), an intracellular thiol. The Cd2+-GSH complex leads to the 
detoxification of Cd2+ (Mah & Jalilehvand, 2010).  
The Role of Cadmium and Carcinogenesis 
 Exposure to Cd2+ has many implications in the body, such as induction of IEGs and 
other detoxifying genes, increased production of reactive oxygen species (ROS), and 
interactions with DNA damage repair systems. Similar to arsenic, Cd2+ induced the 
overexpression of IEGs, which play a role in the stimulation of cell proliferation. This 
implicates Cd2+ toxicity in promoting multi-stage carcinogenesis (Cohen, 1998). Under 
physiological conditions, Cd2+ does not participate in reduction-oxidation reactions, but 
oxidative stress is implicated to play a role in cadmium-induced carcinogenesis. A study 
found increased levels of ROS both in vitro and in vivo, which is mediated by Cd2+ exerting 
an inhibitory effect on antioxidant enzymes (Lui, Qu, & Kadiiska, 2009). These reactive 
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species could lead to chromosomal aberrations, gene mutations, and DNA damage (Joseph, 
2009).  
 There is evidence that Cd2+ disrupts three types of DNA repairs systems: base 
excision repair (BER), nucleotide excision repair (NER), and mismatch repair (MMR). 
Under normal conditions, BER corrects small lesions in the DNA by glycosylases that 
identify damaged bases, recognition of apyrimidinic/apurinic sites, cleavage of these sites, 
and synthesis the correct bases by DNA polymerase (Memisoglu & Samson, 2000). Cd2+ 
affects the initial step of BER, the recognition and removal of damaged bases by inactivated 
proteins involved in these steps . (Giaginis, Gatzidou, & Theocharis, 2006). NER functions 
to correct larger, damaged pieces of DNA by unwinding the DNA, generating incisions 
and excising the DNA, and repair by DNA polymerase and ligase (Costa, Chiganças, da 
Silva Galhardo, Carvalho, & Mench, 2003). It has been found that Cd2+ by substituting 
itself for zinc and by binding to negatively charged molecules and changing the 
confirmation and disturbing DNA-protein interactions that are essential for the repair 
process (Giaginis, Gatzidou, & Theocharis, 2006). MMR systems repair DNA mismatches 
that occur from replication and recombination by recognizing and excising the incorrect 
DNA and synthesizing the correct DNA using the parental strand as a template (Hsieh, 
2001). Like BER, Cd2+ affects the initial step of base repair by interfering with ATP 
binding and the hydrolysis enzymes of MMR enzymes, which reduce the ability of their 
binding affinity and their function to discriminate between correct and mismatched bases 





Cadmium and its Implications in Urinary Carcinoma 
 Epidemiological studies focusing on the association between Cd2+ and urinary 
carcinoma have found contradicting studies which show both no evidence and significant 
evidence of this association. A study that looked at the concentrations of Cd2+ in red blood 
cells and plasma found no significant difference in those with urological malignancies 
compared to those with benign diseases (Feustel & Wennrich, 1986). A more recently 
conducted case-controlled study in Montreal, Canada found a weak association between 
occupational exposure to Cd2+ and an increased risk of urinary carcinoma (Siemiatycki, 
Dewar, Nadon, & Gérin, 1994). Furthermore, two case-controlled studies in Tunisia and 
Belgium found increased levels of Cd2+ blood concentrations were associated with an 
increased risk of bladder cancer (Feki-Tounsi, et al., 2013) (Kellen, Zeegers, Hond, & 
Buntinx, 2007). Taken together, albiet the study by Feustel & Wennrich found no evidence 
of urinary carcinoma and Cd2+ exposure, others studies have demonstrated an association 













Figure 3. Proposed mechanisms of cadmium toxicity and carcinogenesis (Adapted from Waisberg, Joseph, Hale, & Betersmann, 
2003).
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 The UROtsa model was initially cultured from ureter cells of a 12-year old female 
and subsequently immortalized via the SV40 large T antigen. Although immortalized, the 
cells did not display properties of neoplastic cells such as growth on soft agar and 
subsequent tumor development in athymic mice (Petzoldt, Leigh, Duffy, Sexton, & 
Masters, 1995). These cells form an undifferentiated monolayer in culture, but under 
serum-free conditions have shown to undergo partial differentiation and resemble 
structures of the intermediate layer of the bladder; specifically there were areas of 
multicellular organoid structures that contained abundant intermediate filaments 
resembling a differentiated intermediate layer of the bladder urothelium. (Rossi, et al., 
2001). In addition, the UROtsa cell line was transformed via exposure to 1µM sodium 
arsenite (NaAsO2) or 1µM cadmium chloride (CdCl2), which led to the creation of six 
As3+ and seven Cd2+ independently transformed cell lines. In contrast to the parental cell 
line, both of the transformed lines produced growth of colonies on soft agar and tumors in 
athymic mice (Sens, et al., 2004). Taken together, this model allows for comparison 
between the cultured cell lines and their corresponding heterotransplant tumors.  
Goals of the Present Study 
 
 This study was performed in two parts in order to further our understanding of 
muscle-invasive urinary carcinoma and cancer stem cells isolated from the cancer cell 
lines. Muscle-invasive bladder cancer has been shown to have 5-year survival rates of 
only 15% of patients who have been diagnosed with stage T4 urinary carcinoma (Goebell 
& Knowles, 2010). In the first part of the study, we first sought to determine if 
heterotransplant tumors generated from the transformed UROtsa cell culture model are 
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enriched in markers of the basal subtype of muscle-invasive urinary carcinoma. 
Secondly, was to determine if the UROtsa cell lines transformed by As3+ and Cd2+ also 
reflect the basal subtype of muscle-invasive urinary carcinoma and if this subtype 
signature is enriched in the putative cancer stem cells isolated from the corresponding 
transformed cell lines. Lastly, we wish to determine if the parental UROtsa cell line 
contains a population of putative cancer stem cells, which have a gene signature of the 
basal subtype of muscle-invasive bladder cancer. To address the above questions, we 
determined the expression level of 9 basal and 16 luminal markers in the heterotransplant 
tumors, cell lines, and spheroids, and performed western blotting of the cell lines and 
immunohistochemical staining of tumors. By understanding which subtype of muscle-
invasive urinary carcinoma our model system fits, we can further characterize our 
UROtsa model and can study a toxicity-based carcinogenic model of muscle-invasive 
bladder cancer.  
  The second part of this study was to determine the stability of the putative cancer 
stem cell gene signature of the parental UROtsa and As3+ and Cd2+ transformed isolated 
cancer stem cells when cultured under conditions identical to the parent culture and 
serum-free culture conditions, which are used to isolate the cancer stem cells. Our 
laboratory has previously cultured the parental UROtsa cells under serum-free culture 
conditions and found the cells, once confluent, developed multicellular organoid 
structures containing intermediate filaments and cells located apically in the structures 
appeared to be more differentiated (Rossi, et al., 2001). To do this, triplicate samples of 
the putative cancer initiating cells were grown in regular culture flasks in serum-
containing media or in serum-free media. Total RNA samples were isolated when the 
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spheroids reach confluency (P1), and passages 4 and 8 (P4 and P8). The ability to 
investigate the differences found in the gene expression between the original cell line and 
its spheroid and the stability of the gene signature will allow us to better understand the 
interactions of these two distinct cell populations in culture and how putative cancer stem 






 UROtsa cells were initially cultured and developed in order to provide an in vitro 
model of normal urothelium (Petzoldt, Leigh, Duffy, Sexton, & Masters, 1995) and 
further characterized in this laboratory (Rossi, et al., 2001). The cells were cultured in 
serum-containing media, which was composed of Dulbecco’s modified Eagle’s medium 
(DMEM) (Sigma-Aldrich, St. Louis, MO; D5523) supplemented with 5% vol/vol fetal 
bovine serum (FBS) (Gibco/ThermoFisher Scientific, Grand Island, NY; 16000-044) and 
serum-free media, which was composed of of a 1:1 mixture of DMEM and Ham’s F-12 
(Sigma-Aldrich, St. Louis, MO; N6760) supplemented with insulin (5g/mL), transferrin 
(5g/mL), hydrocortisone (36ng/mL), epidermal growth factor (10ng/mL), selenium 
(5ng/mL), and triiodothyronine (4pg/mL). Both types of media cultures were incubated at 
37°C in 5% CO2:95% air atmosphere. Upon reaching confluency, cells were subcultured 
at a 1:4 ratio using trypsin-EDTA (0.05%, 0.02%) and fed fresh growth medium every 
three days. 
 In the interest of gaining valuable knowledge of the toxic effect of As3+ and Cd2+ 
on urothelial cells, a model of metal-induced urothelial carcinoma was created using the 
UROtsa bladder cell line. To do this, UROtsa cells were transformed by culturing the 
cells with media which contained either 1µM NaAsO2 (Sigma-Aldrich, St. Louis, MO; 
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S7400) or 1µM CdCl2 (Sigma-Aldrich, St. Louis, MO; C1016). The cells were continued 
to be exposed to these metals  and were tested for their ability to form colonies on soft 
agar every 5 passages (Sens, et al., 2004).  
 For the formation of the spheroids, cells from the parental UROtsa, six As3+ and 
seven Cd2+-transformed cell lines were seeded in T-25cm2 Ultra-low attachment flasks 
(Corning Inc., Corning NY; CLS3815) at a density of 1 x 105 cells. The serum-free 
growth medium for these cells is mentioned above. The cells were allowed to form 
spheres for eight days before harvesting by centrifugation for RNA isolation. 
Animals 
 The mouse heterotransplants were produced as previously described (Sens, et al., 
2004). Briefly, the As3+ and Cd2+-transformed cell lines were injected at a dose of 1 x 106 
cells in the dorsal thoracic midline of athymic nude (NCr-nu/nu) mice. Mice were 
sacrificed ten weeks post-implantation or when clinical conditions dictated by CO2 
inhalation and euthanasia and conformed to American Veterinary Medical Association 
Guideline on Euthanasia. This study was approved under protocol IACUC #1117-2C by 
the University of North Dakota Care Committee and adhered to all recommendations in 
the Guide for the Care and Use of Laboratory Animals of the NIH.  
RNA Isolation and Real-Time RT-PCR 
 After cells were harvested by cell scraping and pelleted via centrifugation, total 
RNA was isolated using TRI Reagent (Molecular Research Center, Inc., Cincinnati, OH; 
TR 118) according to manufacturer’s instructions. Total RNA of 0.1µg was purified from 
the cell lines, urospheres, and tumor heterotransplants and subjected to cDNA synthesis 
using the iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA; 
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1708891BUN) in a total volume of 20µL. Real-time RT-PCR was performed using the 
SsoAdvanced Universal SYBR Green Supermix (Bio-Rad Laboratories, Hercules, CA; 
1725274) with 2µL of cDNA and 0.2µM of primers (Bio-Rad Laboratories, Hercules, 
CA and Qiagen, Valencia, CA) in a total volume of 20µL in a CFX96 Touch Real-Time 
PCR Detection System (Bio-Rad Laboratories, Hercules, CA; 1855195). Cycling 
parameters are as follows: denaturation at 95°C for 15 seconds, annealing at 60°C for 30 
seconds, and an extension at 72°C for 30 seconds and amplification was monitored via 
SYBR green fluorescence.  
Immunohistochemistry 
Tumor tissue from mouse tumor transplants was fixed in 10% neutral-buffered 
formalin for 16-18 h. The fixed tissue samples were transferred to 70% ethanol and 
dehydrated in 100% ethanol. The dehydrated tissue samples were cleared in xylene, 
infiltrated, and embedded in paraffin. Serial sections were cut at 3-5µm for use in 
immunohistochemical protocols. Prior to immunostaining, sections were immersed in 
preheated Target Retrieval Solution (Dako, Carpinteria, CA) and heated in a steamer for 
20 min. The sections were allowed to cool to room temperature and immersed into TBS-
T for 5 min. The primary antibodies were localized using Dako peroxidase conjugated 
EnVision plus for rabbit primary antibodies or a Dako peroxidase conjugated EnVision 
plus dual link antibody for mouse primary antibodies at room temperature for 30 min. 
Liquid diaminobenzidine (Dako) was used for visualization. Counter staining was 
performed for 8 min. at room temperature using Ready-to-use Hematoxylin (Dako). 
Slides were rinsed in distilled water, dehydrated in graded ethanol, cleared in xylene, and 
cover-slipped. Two pathologists judged the presence and degree of immune-reactivity in 
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the specimens. The scale used was 0 to +3 with 0 indicating no staining, +1 staining of 
mild intensity, +2 staining of moderate intensity, and +3 staining of strong intensity. 
Table 1. Immunohistochemical Analysis Antibodies 
Antigen Source Cat. No. Dilution/Concentration 
Keratin 1 Invitrogen PA5-26699 1:100 
Keratin 5 Invitrogen PA5-29670 1:400 
Keratin 6 Santa Cruz  sc-514520 1:500 
Keratin 7 Dako (Agilent) M7018 1:50 
Keratin 14 Invitrogen PA5-16722 1:400 
Keratin 16 Abcam ab8741 1:40 
Keratin 17 Dako (Agilent) M7046 1:20 
Keratin 19 Abcam ab15463 1:100 
Keratin 20 Invitrogen PA5-22125 1:100 
CD44 R&D Systems MAB7045 10g/ml 
P-cadherin Santa Cruz  sc-7893 1:200 
TP63 Abnova MAB10290 1:100 
CD24 Invitrogen MA5-11833 1:10 
 
Statistical Analysis 
Statistical analysis consisted of Fisher’s LSD testing performed by Graphpad 
PRISM 7.02. All experiments were done in triplicates and the data is plotted as the mean 





Basal and luminal marker gene expression in As3+ and Cd2+-transformed UROtsa 
cell derived tumor transplants 
 The gene signature patterns that identify normal and malignant breast cancer 
tissue has led researchers to study if these unique patterns exist in other tissue types. Choi 
and coworkers identified 25 marker genes (Table 2) that define the basal and luminal 
subtype of muscle-invasive bladder cancer (MIBC) (Choi, et al., 2014). Using these 
genes, the expression of tumor transplants generated from the As3+ and Cd2+-transformed 
UROtsa cells was determined to see if they associated with the basal or luminal subtypes 
of MIBC. To do this, total RNA was isolated from the tumors of the six As3+ and seven 
Cd2+-transformed cell lines and subjected to real-time RT-PCR analysis of the 25 marker 
genes. In addition, the tumors were analyzed for and then normalized to five 
housekeeping genes, ACTB (β-actin), B2M (β-2-microglobulin), HPRT1 (hypoxanthine 
phosphoribosyltransferase 1), RPLP0 (60S acidic ribosomal protein P0), and UBC 
(ubiquitin C). This was done so that direct comparison of the mRNA from the UROtsa 




Table 2. Real-Time RT-PCR Analysis Primers 
Gene Molecular Subtype 
Catalog No./Unique 
Assay ID No. 
Company 
CD24 Luminal QT00216811 Qiagen 
CYP2J2 Luminal qHsaCID0016825 Bio-Rad 
ERBB2 Luminal qHsaCID0012766 Bio-Rad 
ERBB3 Luminal qHsaCID0018397 Bio-Rad 
FABP4 Luminal qHsaCID0036778 Bio-Rad 
FGFR3 Luminal qHsaCED0042267 Bio-Rad 
FOXA1 Luminal qHsaCED0002547 Bio-Rad 
GATA3 Luminal qHsaCID0017793 Bio-Rad 
GPX2 Luminal qHsaCID0014084 Bio-Rad 
KRT7 Luminal qHsaCED0038533 Bio-Rad 
KRT8 Luminal qHsaCED0038745 Bio-Rad 
KRT18 Luminal qHsaCED0035037 Bio-Rad 
KRT19 Luminal qHsaCED0046788 Bio-Rad 
KRT20 Luminal qHsaCID0007981 Bio-Rad 
PPARG Luminal qHsaCED0044425 Bio-Rad 
XBP1 Luminal qHsaCID0010491 Bio-Rad 
CDH3 Basal qHsaCID0015341 Bio-Rad 
CD44 Basal qHsaCID0013679 Bio-Rad 
KRT1 Basal qHsaCID0011275 Bio-Rad 
KRT5 Basal qHsaCED0005398 Bio-Rad 
KRT6A Basal qHsaCED0036985 Bio-Rad 
KRT6B Basal qHsaCED0003069 Bio-Rad 
KRT6C Basal qHsaCED0046712 Bio-Rad 
KRT14 Basal qHsaCED0047868 Bio-Rad 
KRT16 Basal qHsaCED0047866 Bio-Rad 
KRT17 - qHsaCID0023841 Bio-Rad 
TP63 - qHsaCIP0039056 Bio-Rad 
 
 Following normalization, a Principal Component Analysis (PCA) was performed 
on the integrated data. The first principal component explained 52.63% of the total 
variation and the second principal component explained a further 17.43%, which totals to 
70.06% of the total variation explained in these two principal components. As visualized 
in the PCA plot (Figure 4A), the transplanted tumors generated from the As3+ and Cd2+-
transformed UROtsa cell lines had similar expression patterns, except for one sample 
(As#5), in the first principal component, PC1. In addition, total RNA isolated from the 
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parental UROtsa cells was subjected to PCA and it was found to be distinct from the 
MIBC and As3+ and Cd2+-transformed tumor samples. 
 Unsupervised hierarchical clustering was employed to determine the tumor 
subtypes of the As3+ and Cd2+ transformed tumors. Analysis of the data found that the 
samples clustered into three distinct groups located at the top, middle, and bottom of the 
dendrogram (Figure 4B). The group at the top showed high expression of the luminal 
marker genes and low expression of the basal marker genes. Conversely, the group at the 
bottom showed low expression of the luminal marker genes and high expression of the 
basal marker genes. The group located in the middle showed neither high nor low 
expression of the basal and luminal marker genes. All of the tumor transplants generated 
by the As3+ and Cd2+ transformed cell lines clustered with the basal subtype of MIBC 
located at the bottom of the dendrogram. The cluster made by the UROtsa samples can be 
further divided into two subtypes: one that consists of six tumors from the Cd2+ 
transformed cells (Cd #2, Cd #4, Cd #5, Cd #6, and Cd #7) and three isolates of the As3+ 
(As #2, As #3, and As #5) and the second which consist of one Cd2+ isolate (Cd #1), three 
As3+ isolates (As #1, As #4, and As #6). The parental UROtsa cell line sample has a 
distinct expression pattern not associated with any of the three subtypes. 
46 
 
Figure 4. Gene expression pattern analysis in the As3+ and Cd2+ tumor transplants. 
(A). Principal component analysis (PCA) plot of the As3+ and Cd2+ tumor transplants, 
MIBCs, and parental UROtsa cell line. The principal components, PC1 and PC2, were 
calculated form the 25 MIBC marker genes. (B). Heat map and dendrogram of the 25 
MIBC marker genes. Each column represents one of the 25 marker genes and each row 
represents a tumor sample. The dendrogram was generated using hierarchical clustering 
based on Pearson’s dissimilarity and Ward’s linkage. 
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 The expression of 25 MIBC marker genes was determined for the tumor 
heterotransplants generated from the six independent isolates of the As3+ and seven 
independent isolates of the Cd2+-transformed UROtsa cells (Figure 5A and 5B). Analysis 
of the gene expression profiles demonstrated a clear trend for higher expression of genes 
associated with the basal subtype of MIBC. A few exceptions were noted; the first was 
that all the tumors displayed low expression P-cadherin (CDH3), a marker of basal 




























Figure 5. Gene expression analysis of basal and luminal marker genes in the 
heterotransplant tumors produced by the As3+ and Cd2+-transformed UROtsa cells. 
Real-time RT-PCR analysis of basal and luminal marker genes in the As3+ (A) and Cd2+ 
(B) heterotransplants. The analysis was done in triplicates and plotted as ± SD on a log 




Immunohistochemical expression and localization in As3+ and Cd2+-transformed 
UROtsa cell derived tumor transplants 
 Immunohistochemical analysis was executed on tumors generated from the As3+ 
and Cd2+-transformed cells lines in order to determine the localization and expression 
level of the basal and luminal marker genes. Except for CHD3, there was positive 
staining for all of the basal markers in the tumors. A representative staining of each of the 
basal markers is shown for the tumor generated from the As3+ (As #3) (Figure 6) and 
Cd2+ (Cd #3)-transformed cell line (Figure 7). An independent assessment by two 
pathologists found the percent of individual tumors with positive staining for each basal 
marker in conjunction with the level of expression judged on a scale from 0 to +3 (Table 
3) and the percent of tumor cells stained for each of the basal markers. The level of 
expression for each of the basal markers was found to be strong for the tumors, with 
expression intensities between +2 and +3. KRT5 was found to the basal marker with the 
highest percentage of stained tumor cells, with percentages between 70 and 90%. The 
lowest number of stained tumor cells was found when staining for KRT16, with 
percentages between 5 and 50%. The other basal markers were found to be intermediate 
between these two markers and generally followed the pattern of KRT5 > KRT1 > 
KRT14 ≥ CD44 > KRT6 > KRT16. No correlation was found between the mRNA levels 






Table 3. Immunostaining of basal protein markers in As3+ and Cd2+ tumor transplants. 
 
Group 
KRT1 KRT5 KRT6 KRT14 KRT16 CD44 
INT % INT % INT % INT % INT % INT % 
As #1 3+ 60 3+ 90 3+ 20 3+ 90 3+ 10 3+ 70 
As #2 3+ 50 3+ 80 3+ 60 3+ 80 3+ 40 3+ 60 
As #3 3+ 50 3+ 90 3+ 60 3+ 80 3+ 20 3+ 30 
As #4 3+ 40 3+ 90 3+ 60 3+ 90 3+ 50 3+ 70 
As #5 3+ 40 3+ 80 2+ 60 3+ 30 3+ 20 3+ 30 
As #6 3+ 70 3+ 90 3+ 40 3+ 90 3+ 40 3+ 50 
Cd #1 3+ 50 3+ 90 3+ 60 3+ 90 3+ 40 3+ 40 
Cd #2 3+ 50 3+ 70 2+ 20 3+ 60 1+ <5 3+ 70 
Cd #3 3+ 70 3+ 90 3+ 40 3+ 30 2+ 10 2-3+ 40 
Cd #4 3+ 80 3+ 90 3+ 40 3+ 50 2+ 20 2-3+ 50 
Cd #5 3+ 80 3+ 90 3+ 40 3+ 60 2+ 20 2-3+ 30 
Cd #6 3+ 70 3+ 90 2+ 40 3+ 60 2+ 10 2-3+ 50 
Cd #7 3+ 80 3+ 90 3+ 20 3+ 50 2+ 10 2-3+ 50 
 
INT: Intensity of staining 
% : % of cells staining for a marker 
3+ : Strong staining 
2+ : Moderate staining 
2-3+ : Moderate to strong staining 
































Figure 6. Immunohistochemical staining for basal gene markers in heterotransplant 
tumors generated from the As3+ transformed cell line (As #3).  (A) CDH3. There is no 
staining in the well-differentiated or less differentiated areas of the tumor transplants. (B). 
CD44. There is no to weak staining in the center of the tumor nests, whereas the less 
differentiated peripheral cell membranes stain strongly for CD44. (C). KRT1. There is 
strong staining in the well-differentiated areas of the tumor, whereas the less 
differentiated cells show weak staining. (D). KRT5. There is strong staining in both the 
well-and less differentiated of the tumor. (E). KRT6. There is strong staining in the well-
differentiated areas of the tumor, while the less differentiated areas show no to weak 
staining. (F). KRT14. The well-differentiated cells in the center of the tumor nests show 
no to weak staining and the less differentiated peripheral cells are strongly positive for 
KRT14. (G). KRT16. There is strong staining for KRT16 in the well-differentiated cells, 
whereas the less differentiated cells show no staining. * Indicates well-differentiated 
areas of the tumor. # indicates less differentiated areas of the tumor. The blue/purple 
color indicates the nuclei which are counterstained with hematoxylin and the brown color 
































Figure 7. Immunohistochemical staining for basal gene markers in heterotransplnat 
tumors generated from the Cd2+ transformed cell line (Cd #3). (A) CDH3. There is no 
staining in the well-differentiated or less differentiated areas of the tumor transplants. (B). 
CD44. There is no to weak staining in the center of the tumor nests, whereas the less 
differentiated peripheral cells stain strongly for CD44. (C). KRT1. There is strong 
staining in the well-differentiated, areas of the tumor, whereas the less differentiated cells 
show weak staining. (D). KRT5. There is strong staining in both the well-and less 
differentiated of the tumor. (E). KRT6. There is strong staining in the well-differentiated 
areas of the tumor, while the less differentiated areas show no to weak staining. (F). 
KRT14. The well-differentiated cells in the center of the tumor nests show no to weak 
staining and the less differentiated peripheral cells are strongly positive for KRT14. (G). 
KRT16. There is strong staining for KRT16 in the well-differentiated cells, whereas the 
less differentiated cells show no staining. * Indicates well-differentiated areas of the 
tumor. # indicates less differentiated areas of the tumor. The blue/purple color indicates 
the nuclei which are counterstained with hematoxylin and the brown color is indicative of 
the presence of the protein. Images are at a magnification of 200X.  
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 The immunohistochemical analysis of the As3+ and Cd2+-transformed UROtsa cell 
generated tumors identified distinct nests of cells are clusters of well-differentiated 
carcinoma cells, which are surrounded by stroma. The nests consisted of centers of well-
differentiated cells with intracellular bridges and keratinization and less differentiated 
basal-like cells at the periphery. The staining intensity of the basal markers was distinct 
between these two areas for the tumors (Figures 6 and 7 and Table 3). It can be seen that 
the basal marker CD44 showed moderate to strong staining in the less differentiated, 
peripheral cells, whereas the well-differentiated cells at the center showed weak staining. 
In contrast, KRT1, KRT6, and KRT16 showed strong staining in the well-differentiated 



















Table 4. Localization of basal protein markers in different histological areas of the As3+ and Cd2+ tumor transplants. 
Group Well-differentiated cells in the center of tumor nests Peripheral less differentiated cells 
 KRT1 KRT5 KRT6 KRT14 KRT16 CD44 KRT1 KRT5 KRT6 KRT14 KRT16 CD44 
As #1 3+ 3+ 3+ 3+ 3+ 0-1+ +1 3+ 0-1+ 3+ - 3+ 
As #2 3+ 3+ 3+ 3+ 3+ 0-1+ +1 3+ 0-1+ 3+ - 3+ 
As #3 3+ 3+ 3+ 0-1+ 3+ 0-1+ +1 3+ 0-1+ 3+ - 3+ 
As #4 3+ 3+ 3+ 3+ 3+ 0-1+ +1 3+ 0-1+ 3+ - 3+ 
As #5 3+ 3+ 2+ 0-1+ 3+ 0-1+ +1 3+ 0-1+ 3+ - 3+ 
As #6 3+ 3+ 3+ 3+ 3+ 0-1+ +1 3+ 0-1+ 3+ - 3+ 
Cd #1 3+ 3+ 3+ 3+ 3+ 0-1+ +1 3+ 0-1+ 3+ - 3+ 
Cd #2 3+ 3+ 2+ 0-1+ 1+ 0-1+ +1 3+ 0-1+ 3+ - 3+ 
Cd #3 3+ 3+ 3+ 0-1+ 2+ 0-1+ +1 3+ 0-1+ 3+ - 2-3+ 
Cd #4 3+ 3+ 3+ 0-1+ 2+ 0-1+ +1 3+ 0-1+ 3+ - 2-3+ 
Cd #5 3+ 3+ 3+ 0-1+ 2+ 0-1+ +1 3+ 0-1+ 3+ - 2-3+ 
Cd #6 3+ 3+ 2+ 0-1+ 2+ 0-1+ +1 3+ 0-1+ 3+ - 2-3+ 
Cd #7 3+ 3+ 3+ 0-1+ 2+ 0-1+ +1 3+ 0-1+ 3+ - 2-3+ 
 
3+ : Strong staining 
2+ : Moderate staining 
2-3+ : Moderate to strong staining 




 Three of the luminal gene markers showed staining in the tumor transplants 
(Figure 8 and Table 5). Two of the As3+ (As #1 and As #4) and one Cd2+ (Cd #1) 
transformed cell line generated tumor showed no staining for KRT7, while the rest of the 
tumors showed a variable percentage of staining between 5 and 40%. When present, the 
intensity of the staining was judged to be between +2 and +3. All thirteen of the tumor 
samples showed staining for KRT19 with percentage intensity between 20 and 80% with 
strong staining localized to the periphery which contains the less differentiated areas of 
the tumor nests. The staining was localized to the less differentiated peripheral cells. 
CD24 staining was detected in 1 to 40% cells of the tumor with five of the tumors have 
no greater than 5% of the cells showing positive staining. The staining intensity for CD24 
was between +2 and +3 for all the tumor samples and was present in the well-





































Figure 8. Immunohistochemical staining for luminal marker genes in the 
heterotransplant tumors generated from the As3+ and Cd2+-transformed cell lines. 
(A-C) Staining of the As #3 cell line generated tumor for KRT7 (A), KRT19 (B), and 
CD24 (C). (A) There is strong staining in the well-differentiated cells in the center of the 
tumor nests (*), while the less differentiated peripheral cells (#) are negative for KRT7. 
(B) The tumor nests containing the well-differentiated cells (*) are weakly positive for 
KRT19, whereas there is strong staining for the less differentiated cells (#). (C) There is 
moderate to strong staining in for CD24 in the well-differentiated cells (*), as opposed to 
the less differentiated peripheral cells which are absent for CD24. (D-F) Staining of the 
Cd #3 cell line generated tumor for KRT7 (D), KRT19 (E), and CD24 (F). (D) There is 
strong staining in the well-differentiated cells in the center of the tumor nests (*) for 
KRT7, while the less differentiated peripheral cells (#) are negative. (E) The tumor nests 
containing the well-differentiated cells (*) are negative or weakly positive for KRT19, 
whereas there is strong staining for the less differentiated cells (#). (F) There is moderate 
to strong staining in for CD24 in the well-differentiated cells (*), whereas the less 
differentiated peripheral cells which are absent for CD24. The blue/purple color indicates 
the nuclei which are counterstained with hematoxylin and the brown color is indicative of 
the presence of the protein. Images are at a magnification of 200X. 
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INT: Intensity of staining 
% : % of cells staining for a marker 
3+ : Strong staining 
2+ : Moderate staining 
2-3+ : Moderate to strong staining 




KRT7 KRT19 CD24 
Well differentiated cells in the 
center of tumor nests 
Peripheral less differentiated cells 
   KRT7 KRT19 CD24 KRT7 KRT19 CD24 
INT % INT % INT % INT INT INT INT INT INT 
As #1 - 0 3+ 40 2-3+ 40 - 1+ 2-3+ - 3+ - 
As #2 2+ 10 3+ 20 2-3+ 30 2+ 1+ 2-3+ - 3+ - 
As #3 2+ 5 3+ 30 2-3+ 40 2+ 1+ 2-3+ - 3+ - 
As #4 - 0 3+ 80 2-3+ 5 - 1+ 2-3+ - 3+ - 
As #5 3+ 40 3+ 40 2-3+ 30 3+ 1+ 2-3+ 3+ 3+ - 
As #6 2+ 10 3+ 40 3+ 30 2+ 0-1+ 3+ - 3+ - 
Cd #1 - 0 3+ 40 2-3+ 2 - 0-1+ 2-3+ - 3+ - 
Cd #2 3+ 40 3+ 40 2-3+ 1 3+ 1+ 2-3+ 3+ 3+ - 
Cd #3 3+ 40 3+ 40 2-3+ 5 3+ 0-1+ 2-3+ 3+ 3+ - 
Cd #4 3+ 40 3+ 30 2-3+ 10 3+ 0-1+ 2-3+ 3+ 3+ - 
Cd #5 2-3+ 30 3+ 40 2-3+ 20 2-3+ 0-1+ 2-3+ 2-3+ 3+ - 
Cd #6 2-3+ 30 3+ 40 2-3+ 5 2-3+ - 2-3+ 2-3+ 3+ - 




Basal and luminal marker gene expression in the As3+ and Cd2+-transformed 
UROtsa cell lines and spheroids 
 The mRNA expression of basal and luminal markers was determined in the As3+ 
and Cd2+-transformed cell lines and spheroids isolated from these cell lines. The results 
of this analysis for 9 basal markers showed that six markers were differentially expressed 
in the spheroids isolated from the As3+ transformed cell lines (Figure 9A). The expression 
level of KRT1 was below the level of detection in the As3+ transformed cell lines, but 
showed a significant increase in the spheroids. The expression levels of KRT6B, KRT6C, 
KRT14, and KRT16 were also significantly increased in the spheroids, whereas CDH3 
expression was lower in the spheroids when compared to the As3+-transformed cell lines. 
An identical analysis of the luminal marker genes in the As3+-transformed cell lines and 
spheroids showed an increase in the expression levels of FABP4, FGFR3, and KRT20, 




Figure 9. Gene expression analysis of basal and luminal marker genes in the As3+ 
transformed cell lines and their corresponding spheroids. Real-time RT-PCR analysis 
of basal (A) and luminal (B) marker genes in the As3+ transformed cell lines and 
spheroids. The analysis was done in triplicates and plotted as ± SD on a log base 2 scale 
per transcript of β-actin times 1,000. * indicates significantly different at p ≤ 0.05 from 
cell line. ** indicates significantly different at p ≤ 0.01 from cell line. *** indicates 
significantly different at p ≤ 0.001 from cell line. **** indicates significantly different at 
p ≤ 0.05 from cell line p ≤ 0.0001. 
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 The mRNA expression of basal and luminal markers was determined in the Cd2+-
transformed cell lines and spheroids isolated from these cell lines. Similar results were 
obtained for the basal markers in the Cd2+-transformed cell lines and spheroids with there 
being an increase in expression of KRT1, KRT6B, KRT6C, KRT14, and KRT16 and a 
decrease in the expression of CDH3 (Figure 10A). Analysis of the luminal marker genes 
in the Cd2+-transformed cell lines and spheroids show an increase in the expression of 
FABP4 and decreases in expression of CYP2J2, FOXA1, GATA3, and KRT8 (Figure 
10B). These results were similar to the ones obtained in the analysis of the expression of 
the As3+-transformed spheroids compared to the transformed cell line with both showing 
an increase in the expression of FAPB4 and decreases in FOXA1 and GATA3. However, 
the As3+-transformed cell line isolated spheroids showed significant increases in FGFR3 
and KRT20, whereas the Cd2+-transformed cell line isolated spheroids showed decreases 




Figure 10. Gene expression analysis of basal and luminal marker genes in the Cd2+ 
transformed cell lines and their corresponding spheroids. Real-time RT-PCR analysis 
of basal (A) and luminal (B) marker genes in the Cd2+ transformed cell lines and 
spheroids. The analysis was done in triplicates and plotted as ± SD on a log base 2 scale 
per transcript of β-actin times 1,000. * indicates significantly different at p ≤ 0.05 from 
cell line. ** indicates significantly different at p ≤ 0.01 from cell line. *** indicates 
significantly different at p ≤ 0.001 from cell line. **** indicates significantly different at 
p ≤ 0.05 from cell line p ≤ 0.0001. 
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Parental UROtsa cells produce nodules with areas of squamous differentiation 
 Although the tumors generated from the As3+ and Cd2+-transformed cell lines 
produced prominent areas of focal squamous differentiation, it is unknown whether or not 
the parental UROtsa cells express these same areas of squamous differentiation when 
placed under in vivo conditions. Because this cell line is non-tumorigenic and does not 
produce tumors when injected into athymic mice, the parental UROtsa cell line and 
spheroids isolated from these cells were mixed with Corning® Matrigel® and 
subcutaneously injected under the skin of immune compromised (NCr-nu/nu) mice. After 
seven to ten days, the subcutaneous nodules were harvested and processed. Sections were 
H & E stained and examined for nests of cells (Figure 11A and 11B). It was found that 
these nests were composed of irregular shaped cells with branches or angular formations. 
The nodules from the parental UROtsa cells and spheroids were also stained for KRT5, to 
confirm an epithelial identity, and KRT6, a marker shown to identify areas of squamous 
differentiation in UROtsa tumor cells (Choi, et al., 2014). The cells stained positive for 
KRT5 (Figure 11C), whereas the staining for KRT6 (Figure 11D) was negative.  
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Figure 11. Histology and immunohistochemical staining of nodules formed by 
UROtsa cells injected with Matrigel® in immune compromised mice. Histology of a 
nodule formed by UROtsa cells at 100X magnification (A) and 200X magnification (B). 
Nests of epithelial cells of various shape and size seen in the Matrigel® (arrows). Many 
of the nests are irregular in shape with branches or angular formations, while a few nests 
are round or oval in shape, similar to the von Brunn’s nests in the human bladder. 
Immunohistochemical staining for the basal marker genes KRT5 (C) and KRT6 (D). The 
epithelial nests (arrow) stain strongly for KRT5 and are absent for KRT6. The spindle 








Basal and luminal marker gene expression in the parental UROtsa cell line and 
spheroids 
 The expression of 9 basal and 16 luminal marker genes was assessed in the 
parental UROtsa cell line and spheroids, which are generated from the parental cell line. 
The results of the basal marker genes showed that six genes (KRT1, KRT6A, KRT6B, 
KRT6C, KRT14, KRT16) were significantly elevated in the spheroids compared to the 
parental cell line (Figure 12A). There was a significant decrease in the expression levels 
of CDH3, CD44, and KRT5 in the parental spheroids when compared to the UROtsa cell 
line. The basal marker gene expression results are similar to those found in the As3+ and 
Cd2+-transformed cell lines and spheroids, with both having increased expression levels 
of KRT1, KRT6B, KRT6C, KRT14, and KRT16 and decreased expression of CDH3. For 
the luminal marker genes, there was a significant increase in the expression of CD24, 
FABP4, and KRT20 whereas there was a significant decrease in the expression of ten 
genes (CYP2J2, ERBB3, FGFR3, FOXA1, GATA3, GPX2, KRT7, KRT8, KRT18, and 
KRT19) (Figure 12B).  
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Figure 12. Gene expression analysis of basal and luminal marker genes in the 
parental UROtsa cell line and spheroids. Real-time RT-PCR analysis of basal markers 
(A) and luminal marker genes (B) in the parental UROtsa cell line and spheroids. The 
analysis was done in triplicates and plotted as ± SD on a log base 2 scale per transcript of 
β-actin times 1,000. * indicates significantly different at p ≤ 0.05 from parental UROtsa 
cell line. ** indicates significantly different at p ≤ 0.01 from parental UROtsa cell line. 
*** indicates significantly different at p ≤ 0.001 from parental UROtsa cell line. **** 
indicates significantly different at p ≤ 0.0001 from parental UROtsa cell line. 
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Expression of KRT17 and TP63 in the UROtsa Model System 
 In addition to the 25 MIBC marker genes identified by Choi and co-workers, 
research has found cytokeratin 17 (KRT17) is a basal-cell specific cytokeratin, which 
when highly expressed, identifies urothelial stem cells (He, et al., 2009). For this reason, 
we wished to know the expression of KRT17 in our As3+ and Cd2+ heterotransplant 
tumors and found high expression of KRT17 in the six As3+ and seven Cd2+ derived 
tumors (Figure 13A). Next, we analyzed protein expression via immunohistochemistry 
for KRT17 in the heterotransplant tumors and found strong staining in the well-
differentiated areas of the tumor (*) and weak staining in the less differentiated cells (#) 
in the As3+-derived tumor (Figure 13B). On the contrary, the Cd2+-derived 
heterotransplant tumor showed weak staining in the well-differentiated cells (*) and 
strong staining in the less-differentiated cells (#) (Figure 13C). Lastly, we analyzed the 
mRNA expression of KRT17 in our parental UROtsa and six As3+ and seven Cd2+-
transformed cell lines and spheroids derived from these lines. KRT17 expression was 
found to be highly expressed in the cells lines and this expression was significantly 
increased in the respective spheroids (Figure 13D).  
 Previously, the UROtsa parent cell line was immortalized via the SV40 large T-
antigen (Petzoldt, Leigh, Duffy, Sexton, & Masters, 1995). The effect of this virus is not 
known, but has shown to interact with p53 (Lilyestrom, Klein, Zhang, Joachimiak, & 
Chen, 2006), which in turn could influence the function of p53. For this reason, the 
mRNA expression of tumor protein 63 (TP63), a member of the p53 family (Wei, Zaika, 
& Zaika, 2011), was determined in the As3+ and Cd2+ UROtsa-derived tumors and was 
found to be moderately to highly expressed in all the tumors (Figure 13E). 
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Immunohistochemical analysis of TP63 in the heterotransplant tumors found moderate 
expression in the less differentiated areas of the tumor (#) with no staining in the well-
differentiated areas of the tumor nests (*) in both the As #2 and Cd #3 cell line-derived 
tumors (Figure 13 F & G). Lastly, we analyzed mRNA expression of TP63 in our 
parental UROtsa and six As3+ and seven Cd2+-transformed cells lines and derived 
spheroids and found high expression in the cell lines with significantly decreased 




























Figure 13. Expression of KRT17 and TP63 in the parental UROtsa and As3+ and Cd2+-transformed UROtsa model. Real-time RT-PCR of KRT17 in the 
As3+ and Cd2+ tumors (A) and staining of the As #3 (B) and Cd #2 (D) cell line generated tumor for KRT17. mRNA expression of parental UROtsa, As3+ and 
Cd2+ cell lines and spheroids for KRT17 (D). Real-time RT-PCR of TP63 in the As3+ and Cd2+ tumors (E) and staining of the As #3 (G) and Cd #2 (H) cell line 
generated tumor for TP63. mRNA expression of parental UROtsa, As3+ and Cd2+ cell lines and spheroids (F). The analysis was done in triplicates and plotted as 
± SD on a log base 2 scale per transcript of β-actin times 1,000. * indicates significantly different at p ≤ 0.05 from cell line. ** indicates significantly different at 
p ≤ 0.01 from cell line. *** indicates significantly different at p ≤ 0.001 from cell line. **** indicates significantly different at p ≤ 0.05 from cell line p ≤ 0.0001. 
* Indicates well-differentiated areas of the tumor. # indicates less differentiated areas of the tumor. The blue/purple color indicates the nuclei which are 

















Stability of the spheroid gene signature in the As3+ and Cd2+-transformed and 
parental UROtsa cells 
 A second goal of this study was to determine the stability of the spheroid gene 
signature. This was accomplished by performing microarray analysis on triplicates of 
spheroids generated from a As3+-transformed cell line (As #4) grown in regular cell 
culture flasks that promote cell attachment in serum-containing media, which is also used 
for the growth of the As #4 cell line. Triplicate samples were subjected to total RNA 
isolation when the spheroids reach confluency (passage 1) and at passages 4 (P4) and 8 
(P8). The results showed that the gene expression signature of the spheroids returned to 
that of the As #4 parent cell line when placed under similar cell culture conditions. Of the 
initial 4,415 differentially expressed genes in the spheroids compared to the As #4 
transformed cell line, by P1 70.9% of those genes had returned to the level of expression 
of the As #4 cell line. This trend continued at P4 and P8 with 89.8% and 95.7%, 
respectively, of the differentially expressed genes returned to the level of the As #4 
transformed parental cell line.  
 The growth and isolation of the spheroids utilizes low attachment plastic culture 
vessels with serum-free growth media, while the parental cell lines are grown in serum-
containing media in vessels that promote cell attachment. It was demonstrated that by 
growing the spheroids in serum-containing growth media in vessels promoting 
attachment, the gene signature returned to that of the As #4 parental cell line. Because of 
these results, we wished to know if the spheroids from the As3+ and Cd2+-transformed cell 
line and parental UROtsa cell line would retain their gene signatures if they were cultured 
in serum-free media in adherent culture vessels. To do this, the spheroids were cultured in 
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serum-free growth media in vessels that promoted cell attachment and isolated at P1, P4, 
and P8.  
 Analysis of the 25 MIBC marker genes in the As #4 transformed cell line, 
spheroid, and passages shows that 84% of the genes are differently expressed in the 
spheroid compared to the parental As #4 transformed cell line. This trend is continued in 
the spheroids placed in regular attachment flasks with serum-free media; the percent of 
differently expressed genes at P1 and P4 is 72, while the percentage increases to 84% at 
P8 (Figure 14).  
Figure 14. Number of differentially expressed genes in the spheroid and passages 
compared to the As3+-transformed cell line when cultured in serum-free conditions. 
The total number of genes and the number of down- and up-regulated is plotted for the 
spheroids and passages cultured in serum-free media.  
 
 The mRNA expression of the basal markers showed an initial decrease in 
expression of CDH3 in the spheroid, but increased expression in the passages (Figure 
15A). CD44 expression showed an increase in the spheroid, but no difference between 
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the parental transformed cell line and the passages (Figure 15B). The expression of KRT1 
was increased in the spheroid, returned to baseline levels in P1 and P4, but saw another 
increase in P8 (Figure 15C). KRT5 expression was increased in the spheroids and all 
three passages (Figure 15D), whereas KRT6A showed the opposite expression and was 
found to be decreased in all of the samples compared to the As #4 transformed cell line 
(Figure 15E). The expression of KRT6B was increased only in the spheroids (Figure 
15F), while KRT6C expression saw increases across all samples (Figure 15G). KRT14 
showed a slight induction in the spheroid, but a great induction in the passages (Figure 
15H). Lastly, KRT16 expression was increased in the spheroid, returned to similar levels 
in P1 and P4, but showed an induction of expression by P8 (Figure 15I).  
 Analyzing the mRNA expression of the luminal markers found increased levels of 
CD24, CYP2J2, ERbβ2, and ERbβ3 (Figure 16A-D) in the spheroids and all three 
passages. There was only an increase in FAPB4 in the spheroid (Figure 16E). FGFR3 
expression was increased in all the samples (Figure 16F), whereas FOXA1 showed 
opposite expression, being decreased in all the samples (Figure16G). There was no 
change in the expression of the transcription factor GATA3 in the spheroid and P4, 
however there was found to be a decrease in P1 and increase by P8 (Figure 16H). GPX2 
expression was found to be increased in the spheroid, P1, P4, and P8 (Figure 16I). 
Conversely, KRT7 expression was decreased in the spheroid and passages compared to 
the As #4 transformed cell line (Figure 16J). KRT8 expression was increased in the 
spheroid and all three passages (Figure 16K). There was increased expression of KRT18 
in P4 and P8 (Figure 16L), whereas there was an increase in expression of KRT19 in the 
spheroid and all three passages (Figure 16M). KRT20 expression was found to be 
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increased in the spheroid, returned to baseline in P1 and P4, but increased again in P8 
(Figure 16N). The receptor PPARγ saw increased expression in the passages (Figure 
16O) and the expression of XBP1 was decreased in the spheroid, but levels returned to 






























Figure 15. Gene expression analysis of basal marker genes in the As3+-transformed cell line, spheroids, and passages. (A-I) 
Real-time RT-PCR analysis of basal markers marker genes in the As3+-transformed cell line, spheroids, and serial passages. The 































Figure 16. Gene expression analysis of luminal marker genes in the As3+-transformed cell line, spheroids, and passages. (A-P) 
Real-time RT-PCR analysis of luminal marker genes in the As3+-transformed cell line, spheroids, and serial passages. . The analysis 
was done in triplicates and plotted as ± SEM per transcript of β-actin. 
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 Analysis of the 25 MIBC marker genes in the Cd #4 transformed cell line, 
spheroid, P1, P4, and P8 grown in serum-free cell culture media showed that 84% of the 
genes are differentially expressed in the Cd #4 transformed cell line compared to the 
spheroid. This high percentage of differentially expressed genes continues in the passages 
where 92% of the genes are differentially expressed in P1, 72% in P4, and 68% in P8 
(Figure 17). These results are similar to what was seen in the As #4 serum-free culture 
analysis with a majority of the genes being differentially expressed throughout the 
spheroid and subsequent passages.  
Figure 17. Number of differentially expressed genes in the spheroid and passages 
compared to the Cd2+-transformed cell line when cultured in serum-free conditions. 
The total number of genes and the number of down- and up-regulated is plotted for the 




While the overall number of differentially expressed genes is similar between the As #4 
and Cd #4 data sets, the Cd #4 gene expression analysis shows a higher ratio up-regulated 
to down-regulated differentially expressed genes.  
 The mRNA expression of the basal subtype specific marker genes showed an 
initial decrease in CDH3 in the spheroid followed by increased expression in the three 
passages (Figure 18A). The expression of CD44 significantly increased in the passages 
(Figure 18B), whereas KRT1 expression increased in the spheroid and returned to 
baseline by P4 (Figure 18C). KRT5 expression was increased in the spheroids, P1, P4, 
and P8 (Figure 18D). The three keratin 6 isoforms (KRT6A, 6B, and 6C) all showed 
increases in the spheroid, but gradually returned to similar expression levels of the Cd #4 
transformed cell line by P8 (Figure 18E-G). KRT14 expression was increased in the 
spheroid and all three passages compared to the Cd #4 transformed cell line (Figure 
18H), whereas KRT18 showed an increase in expression in the spheroid, but decreased in 
the passages and by P8 returned to expression levels of the Cd #4 cell line (Figure 18I). 
The expression of CDH3 and KRT5 was similar in the As #4 and Cd #4 data sets, 
whereas KRT1 and KRT16 expression saw increases in expression in the As #4 model, 
but decreases in expression in the Cd #4 samples.  
 The luminal gene marker expression in the Cd #4 spheroid and passages showed 
an increase of expression in CD24 in the samples (Figure 19A), whereas CYP2J2 had a 
decrease in expression in the spheroid, but showed a significant induction in the passages 
(Figure 19B). There was no change in expression of ERbβ2 in the spheroid, but an 
increase in expression in the passages (Figure 19C). ERbβ3 expression was increased in 
all samples (Figure 19D), however, FAPB4 was only induced in the spheroid (Figure 
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19E). The expression of FGFR3 was increased relative to the Cd #4 cell line, with the 
exception being P4 (Figure 19F). The transcription factor FOXA1 expression was 
decreased in the spheroid, P4, and P8, while increased in P1 (Figure 19G). GATA3 
expression was increased in the spheroids and subsequent passages (Figure 19H). The 
expression of GPX2 was induced in the spheroid, P1, and P8 (Figure 19I). KRT7 
expression was increased in P1 and P4, but returned to baseline levels by P8 (Figure19J). 
The expression of KRT8, KRT18, and KRT19 was increased in the spheroids and 
passages (Figure 19K-M). KRT20 expression was induced in the spheroid and returned to 
baseline levels (Figure 19N), whereas PPARγ was increased in the passages (Figure 
19O). Lastly, the expression of XBP1 initially decreased in the spheroid, but was induced 
in the passages (Figure 19P). The expression of the luminal marker genes CD24, ERbβ3, 
FAPB4, KRT8, KRT19, and PPARγ showed similar expression levels of the spheroids 














Figure 18. Gene expression analysis of basal marker genes in the Cd2+-transformed cell line, spheroids, and passages. (A-I) 
Real-time RT-PCR analysis of basal markers marker genes in the Cd2+-transformed cell line, spheroids, and serial passages. The 































Figure 19. Gene expression analysis of luminal marker genes in the Cd2+-transformed cell line, spheroids, and passages. (A-P) 
Real-time RT-PCR analysis of luminal marker genes in the Cd2+-transformed cell line, spheroids, and serial passages. . The analysis 




 The mRNA expression analysis of the 25 MIBC marker genes in the UROtsa cell 
line, spheroid, and passages cultured in serum-free media showed a great percentage of 
the genes being differentially expressed compared to the parental cell line at the spheroid 
and each passage. Analysis found 84% of the genes were differentially expressed in the 
spheroid and P1, 88% in P4 and 76% in P8 (Figure 20). These trends align with the As #4 
and Cd #4 serum-free cultured spheroids and passages. However, unlike those data sets, 
the UROtsa expression analysis showed a greater ratio of down-regulated to up-regulated 
genes.  
 
Figure 20. Number of differentially expressed genes in the spheroid and passages 
compared to the UROtsa cell line when cultured in serum-free conditions. The total 
number of genes and the number of down- and up-regulated is plotted for the spheroids 





 Analysis of the basal specific marker genes of MIBC found decreased expression 
levels of CDH3 in the spheroid and passages (Figure 21A). The expression of CD44 was 
decreased in the spheroid and increased in P1 and P4 (Figure 21B). KRT1 expression was 
greatly induced in P4 and P8 (Figure 21C) and KRT5 showed an increase in expression 
across all the samples compared to the UROtsa cell line (Figure 21D). The expression of 
the keratin isoforms (KRT6A, 6B, and 6C) was increased in all the spheroids and 
passages, except for P1 in KRT6A (Figure 21E-G). The expression of KRT14 was 
induced in the passages (Figure 21H). Lastly, KRT16 expression was increased in the 
spheroid and P1, but decreased in P4 and P8 (Figure 21I). The expression of CDH3 was 
opposite of what was seen in the As #4 and Cd #4 data sets, however the expression of 
KRT5 and KRT14 was alike in all three.  
 Analysis of the mRNA expression of the luminal MIBC marker genes found 
expression of CD24, CYP2J2, and ERbβ2 to be decreased in the spheroids and passages 
(Figure 22A-C). The expression of ERbβ3 was increased in the spheroid and P4, but 
decreased in P1 (Figure 22D). FABP4 expression was induced in the spheroid and 
decreased in P1 and P4 (Figure 22E). The expression FGFR3 was decreased in the 
spheroids and increased in P1 (Figure 22F). The expression of FOXA1 and GATA3 was 
decreased in the spheroids and passages (Figure 22G-H), whereas GPX2 expression was 
increased in all the samples (Figure 22I). KRT7, KRT8, and KRT18 expression was 
decreased in the spheroids and passages (Figure 22J-L). The expression of KRT19 was 
decreased in P4 and P8 (Figure 22M), whereas expression of KRT20 was induced in the 
spheroid and P1, but returned to similar levels of the UROtsa cell line by P4  
(Figure 22N). Lastly, the expression of PPARγ and XBP1 were decreased in the spheroid 
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and subsequent passages (Figure 22O-P).  The expression of FABP4 and GPX2 in the 
UROtsa serum-free culture model was similar to the results seen in the As #4 and Cd #4  
data, while the expression of CD24, KRT8, and XBP1 showed opposite results. 
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Figure 21. Gene expression analysis of basal marker genes in the parental UROtsa cell line, spheroids, and passages. (A-I) 
Real-time RT-PCR analysis of basal markers marker genes in the parental UROtsa cell line, spheroids, and serial passages. The 
analysis was done in triplicates and plotted as ± SEM per transcript of β-actin. 
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Figure 22. Gene expression analysis of luminal marker genes in the parental UROtsa cell line, spheroids, and passages. (A-P) 
Real-time RT-PCR analysis of luminal marker genes in the parental UROtsa cell line, spheroids, and serial passages. . The analysis 





 Our laboratory has determined that the tumor transplant generated from the As3+ 
and Cd2+-transformed UROtsa cells display a basal gene expression pattern identified by 
a recent study (Choi, et al., 2014) through two different approaches. First the expression 
of mRNA for the 9 basal and 16 luminal marker genes from the tumors derived from the 
six isolates of the As3+ and seven isolates of the Cd2+-transformed UROtsa cells was 
compared to the 73 primary MIBCs selected for analysis in the study by Choi and 
coworkers (Choi, et al., 2014). The results showed that unsupervised hierarchical 
clustering of the samples found that the As3+ and Cd2+ tumors demonstrated a strong 
identify with the basal subtype of MIBCs. These results were supported by comparing the 
mRNA expression levels of the basal and luminal marker genes in the tumors derived 
from the six isolates of As3+ and seven isolates of Cd2+-transformed cells and finding an 
elevated expression of the basal compared to the luminal marker genes.  
 Despite the supporting results of the unsupervised hierarchical clustering and 
comparison of mRNA expression levels of the marker genes, concerns regarding the high 
expression of the keratins in the basal and luminal subtypes and the multiple transcription 
factors associated with the luminal subtype. Because of their association with the 
cytoskeleton, the keratins may have high levels of expression and transcription factors are 
known to exert their influence at low expression levels. However, two of the keratins 
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associated with the luminal subtype (KRT7 and KRT20), showed only modest and no 
expression, respectively.  
 The final piece of evidence that the As3+ and Cd2+-transformed derived tumors 
show characteristics of the MIBC basal subtype is the immunohistochemical expression 
of the basal and luminal markers. Besides CDH3, all of the tumors showed a strong 
staining for the other basal markers. Opposed to the high expression of the basal markers, 
only three luminal markers showed staining in the tumor transplants (CD24, KRT7, and 
KRT19). Therefore, the tumors generated from the As3+ and Cd2+-transformed parental 
UROtsa cells display expression patterns that aligns with the basal subtype of MIBCs.  
 The characterization of the UROtsa-derived tumors as the basal subtype of MIBC 
could be influenced by multiple factors. First, because of the generation of the tumors in 
athymic mice, there is limited influence of immune cells on the tumors, which interrupts 
the interaction of the stroma and tumor. Next, the UROtsa parent cell line was 
immortalized via the SV40 large T-antigen (Petzoldt, Leigh, Duffy, Sexton, & Masters, 
1995). The effect of this virus is not known, but has shown to interact with p53 
(Lilyestrom, Klein, Zhang, Joachimiak, & Chen, 2006), which in turn could influence the 
function of p53. For this reason, the expression of p63, a member of the p53 family (Wei, 
Zaika, & Zaika, 2011), was determined in the UROtsa-derived tumors and was found to 
be expressed in all the tumors.  
 The expression of mRNA for the basal and luminal marker genes was also 
analyzed in the As3+ and Cd2+ transformed cell lines and spheroids generated from each 
of the six As3+ and seven Cd2+ cell lines. These cells lines had expression patterns that 
identified the most with the basal gene signature and this identity was increased in the 
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spheroids isolated from the cell lines. The expression of KRT1, KRT6B, KRT6C, 
KRT14, and KRT16 was increased in the spheroids compared to the As3+ and Cd2+-
transformed cell lines. These basal gene markers were also upregulated in the tumors 
generated from the transformed cells.  
 The next part of this study looked at the mRNA expression of the basal and 
luminal marker genes in the parental UROtsa cell line and the spheroids isolated from 
these cells. The expression levels were compared to the transformed cell lines, tumors 
from these cell lines, and the MIBCs. The results showed that the spheroids from the 
parental UROtsa cells showed increased expression of all the basal keratins (KRT1, 
KRT5, KRT6A, KRT6B, KRT6C, KRT14, and KRT16), whereas there was decreased 
expression of CDH3 and CD44. The increased of expression of five of these six keratins 
was seen in the spheroids isolated from the transformed cells and tumors derived from 
these cell lines along with the decreased expression of CDH3. With the overlapping 
increase of five out of the six basal keratins in the parental UROtsa and As3+ and Cd2+ 
transformed cell line derived spheroids, this suggests that these basal keratins may be 
markers of urinary carcinoma with characteristics of squamous differentiation.  The 
results also suggests that the spheroids isolated from the parental UROtsa cells undergo 
transformation with As3+ and Cd2+ and gain the ability to form tumors in aythmic mice.  
 The study then shifted focus and examined if the gene signature seen in the 
spheroids could be maintained once the spheroids were placed back in conditions used to 
grow the original cell line. The growth and isolation of the spheroids utilizes low 
attachment culture vessels with serum-free growth media, in contrast to the parental cell 
lines, which are grown in vessels promoting attachment with serum-containing growth 
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media. Microarray analysis data found that the gene signature of the spheroids isolated 
from one of the As3+-transformed cell lines (As#4) reverted back to that of the original 
cell line. Upon reaching confluency, over 70% of the differentially expressed genes were 
no longer expressed and seven more serial passages showed that 95% of the genes were 
no longer differentially expressed. These results suggests that a culture environment of 
serum-containing media does not allow for differentiation of our UROtsa model system.    
 In addition, a limited analysis of the 25 MIBC marker genes of the same 
experimental cell culture set-up, except cultured in serum-free media, found an 
expression profile for the As #3, Cd #3, and parental UROtsa cells to be different when 
comparing the cell line to the spheroids and serial passages. The As #3 spheroid and 
serial passages saw increases in the basal markers KRT5 and KRT14, which are markers 
of the basal cell compartment of the bladder (McConkey, Choi, Ochoa, & Dinney, 2016). 
The luminal markers Erb-β2 and Erb-β3 showed increases in the spheroids and serial 
passages compared to the cell line, which suggests an increase in proliferation due to the 
heterodimerization of these co-receptors and subsequent signaling of the PI3K pathway 
(Holbro, et al., 2003). Furthermore, a knockout of FOXA1, a DNA-binding protein that 
plays a role in metabolism and interactions with hormones, has resulted in the 
development of keratinizing squamous metaplasia in mice (Shuman, et al., 2017). Lastly, 
the results showed an increase in glutathione peroxidase 2 (GPX2), which suggests an 
increase in proliferation and ROS (Naiki, et al., 2017). Taken altogether, the As #3 
unique gene signature shows increased levels of growth and proliferation due to increased 
expression of basal cells and reactive oxygen species furthering the development of 
squamous differentiation and urinary carcinoma. 
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 The Cd #3 cell line showed decreases of expression in KRT5 and KRT14, similar 
to those of the As #3 cell line. The luminal marker gene GATA3 was increased in the 
spheroids and serial passages, which could be indicative of decreased invasion and 
progression (Li, et al., 2014). Also increased in expression was the transcription factor X-
box binding protein 1 (XBP1), which has been implicated in the unfolded protein 
response and shown to lead to an increase in innate immune response and a potent 
cytotoxic T-lymphocyte engagement (Overley-Adamson, et al., 2014). Taken together, 
there may be a unique gene signature that is less invasive and a less progressive form of 
urinary carcinoma. 
 The parental UROtsa spheroids and serial passages showed a decrease in 
expression of P-cadherin (CDH3), which has been linked to muscle-invasive disease 
(Mandevilla, et al., 2008) and increases in KRT5 and KRT14. Similar to the As #3 cell 
line, spheroids, and serial passages, the parental UROtsa model showed a decrease in 
expression of FOXA1 and an increase in GPX2. However, the parental UROtsa model 
showed decreases in the expression of GATA3, PPARγ, and XBP1. These results suggest 
the parental UROtsa spheroid and serial passages have increased expression of basal cells 
and invasion and disease progression.  
 Overall, the unique gene signatures found in the spheroids and serial passages 
compared to the original cell lines indicates the role that serum has on the ability to 
differentiate cells and the growth environment of cells directly influences the gene 
expression of those cells and their ability to differentiate into cells with unknown 







AP-1 Activator protein 1 
As3+ Arsenite 
As5+ Arsenate 
ATP Adenosine triphosphate 
BER Base excision repair 
CCND1 Cyclin D1 
Cd2+ Cadmium 
CD24 Cluster of differentiation 24 
CD44 Cluster of differentiation 44 
CdCl2 Cadmium chloride 
CDH3 Cadherin 3 
CYP2J2 Cytochrome P450 family 2 subfamily J member 2 
DMA Di-methylated 
DMEM Dulbecco’s modified Eagle’s medium 
DNA Deoxyribonucleic acid 




ERBB2 Erb-β2 receptor tyrosine kinase 2 
ERBB3 Erb-β2 receptor tyrosine kinase 3 
FABP4 Fatty acid binding protein 4 
FGFR3 Fibroblast growth factor receptor 3 
FOXA1 Forkhead box A1  
GATA3 GATA binding protein 3 
GC Gemcitabine plus cisplatin  
GPX2 Glutathione peroxidase 2 
GSH Glutathione 
H & E Hematoxylin and eosin 
HMOX1 Heme oxygenase 1 
iAs Inorganic arsenic 
IEG Intermediate early genes 
IPA Ingenutiy pathway analysis 
I-κB Inhibitor of κB 
KPNA2 Karyopherin subunit alpha 2 
KRT1 Keratin 1 
KRT14 Keratin 14 
KRT16 Keratin 16 
KRT17 Keratin 17 
KRT18 Keratin 18 
KRT19 Keratin 19 
KRT20 Keratin 20 
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KRT5 Keratin 5 
KRT6A Keratin 6A 
KRT6B Keratin 6B 
KRT6C Keratin 6C 
KRT7 Keratin 7 
KRT8 Keratin 8 
MAPK Mitogen-activated protein kinase 
MDM2 MDM2 proto-oncogene 
MIBC Muscle-invasive bladder cancer  
MMA Mono-methylated 
MMR Mismatch repair 
mRNA Messenger RNA 
MT Metallothionein 
mTOR Mammalian target of rapamycin 
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Methotrexate, vinblastine, doxorubicin, and 
cyclophosphamide 
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NER Nucleotide excision repair 
NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells 
PCA Principle Component Analysis 
PD-1 Programmed cell death protein 
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PPARG Peroxisome proliferator activated receptor gamma 
PTEN 
Phosphatidylinositol (3,4,5)-trisphosphate phosphatase and 
tensin homolog 
RB Retinoblastoma 
RNA Ribonucleic acid 
ROS Reactive oxygen species 
RTK Receptor tyrosine kinase 
SCC Squamous cell carnicoma 
SV40 Polyomavirus simian virus 40 
TP53 Tumor protein 53 
TP63 Tumor protein 63 
TURBT Transurethral resection of the bladder tumor 
UPK1B Uroplakin 1B 
UPK2 Uroplakin 2 
UPK3 Uroplakin 3 
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